secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-05-14T20:36:14+00:00
Accession:  0001437749-26-017082
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Valion Bio posts Q1 net loss of $6.2M; cash falls to $7.2M; advances Entolimod
------------------------------------------------------------------------------

- Net loss $6.2M ($2.23/share) vs $1.5M ($2.52/share) a year ago; operating expenses $5.6M (was $1.4M).
- Cash and equivalents $7.2M at March 31, 2026, down from $12.6M at Dec 31, 2025.
- Government engagement broadened with BARDA, NIAID, and Dept of War for Entolimod as ARS countermeasure.
- Velocity Bioworks CDMO integration advancing; facility supports internal and third-party biologics manufacturing.
- Pipeline includes Entolimod (Animal Rule pathway) and Entolasta (TLR5 agonist for oncology supportive care).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000143774926017082/0001437749-26-017082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000143774926017082/tivc20260405_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer